This Pharma company stock is in focus, where the Shark Tank judge, Namita Thapar is a promoter, has delivered strong results with a 63 percent increase in Net Profit and a dividend recommendation. The Stock hit the 10 percent Upper Circuit Market
With a market capitalisation of Rs. 22,198 Crore, the stock of Emcure Pharmaceuticals opened at Rs. 1,075, around the same level as yesterday’s close, and after opening, it made a high of Rs. 1180.90, hitting the 10 percent Upper circuit mark.
Financial Highlights & Dividend Recommendation
The company reported a 19.46 percent YoY increase in revenue from Rs. 1,771.40 Crore in Q4FY24 to Rs. 2,116.20 Crore in Q4FY25. On a QoQ basis, the company reported an increase of 7.82 percent in revenue from Rs. 1,962.60 Crore in the previous quarter.
Their Net profit saw an increase of 62.80 percent YoY from Rs. 121 Crore to Rs. 197 Crore for the same period. On a QoQ basis, the company reported an increase of 26.28 percent in Net profit from Rs. 156 Crore in the previous quarter.
The sharp rise in net profit on a YoY basis was driven by higher revenue, stable costs, reduced finance expenses, a foreign exchange gain, and a lower tax outgo due to deferred tax benefits.
Domestic business sales stood at Rs. 929 Crore, up 24.80 percent YoY, and International Business sales stood at 1,187 Crore, up 15.60 percent YoY. EBITDA Margin increased from 17.60 percent to 18.40 percent on a QoQ basis, and PAT Margin increased from 6.80 percent to 9.30 percent for the same period.
The Company recommended a final dividend of Rs. 3 per share or 30 percent of the share capital of Rs. 10 per share. The dividend will be subject to approval from the shareholders at the AGM.
Also read: Multibagger stock jumps 3% after receiving ₹192 Cr order for Energy Efficiency Project in Bengaluru
About the Company
Founded in 1981 by Satish Mehta & headquartered in Pune, Emcure Pharmaceuticals Limited is an Indian multinational pharmaceutical company. Emcure has grown into a significant player in the global pharmaceutical industry, with operations in over 70 countries.
It is currently the 12th largest Pharma company in India in terms of Domestic sales for MAT (Moving Annual Total), June 2024. The company focuses on the development, manufacturing, and marketing of a wide range of pharmaceutical products, including tablets, injectables, biologics, and active pharmaceutical ingredients (APIs). Namita Thapar, being the promoter, owns 2.68 percent or 50,71,200 shares in the company.
Written By Abhishek Das
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
